MC 005172
Latest Information Update: 04 Oct 2004
At a glance
- Originator Daiichi Pharmaceutical; Essential Therapeutics [CEASED]
 - Class Antifungals
 - Mechanism of Action Undefined mechanism
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 
Highest Development Phases
- Discontinued Mycoses
 
Most Recent Events
- 04 Oct 2004 Discontinued - Preclinical for Mycoses in Japan (unspecified route)
 - 04 Oct 2004 Discontinued - Preclinical for Mycoses in USA (unspecified route)
 - 26 May 2003 No development reported - Preclinical for Mycoses in Japan (unspecified route)